pharma · Glioblastoma · Unresectable or metastatic soft tissue sarcoma
Philogen
Philogen S.p.A.
Philogen S.p.A is a pharma organization headquartered in SIENA, IT. Primary therapeutic focus areas include Glioblastoma, Unresectable or metastatic soft tissue sarcoma, Cutaneous Squamous Cell Carcinoma, locally advance
Company details
- Status
- Public
- HQ
- Loc. Bellaria, 35, Sovicille, SIENA 53018, IT
- Founded
- 1996
- Employees
- 180
- Programs
- 18
- Drugs
- 29
- Patents
- 0
PH-L19IL2CORK-01/25
Phase 1 · other · Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma
PH-L19IL2CORK-01/25 for Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma is a Phase 1 program (other) at Philogen S.p.A. with 1 ClinicalTrials.gov record(s).
Internal code PH-L19IL2CORK-01/25
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Philogen S.p.A.
- Phase
- Phase 1
- Modality
- other
- Indication
- Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma
- Status
- active
- Trials
- 1